2018 Oral Mucositis Drug Development- Pipeline Analysis Report

May 2018 | | ID: 2B1C7B8EC93EN
VPAResearch

Abstracts

With an estimated $2 billion market value, the Oral Mucositis disease pipeline presents strong opportunities for development of treatment options. Absence of preventive or curative treatment for the Oral Mucositis is encouraging investigators in major companies to focus on pipeline. Further, an increasing trend towards grant announcements is being observed in the segment.

The disease occurs primarily as a result of damage to epithelium by chemoradiation.

Over 30 companies and universities are focusing on developing treatment options for Oral Mucositis.

To assist investigators and funding and regulatory organizations, VPA Research has come up with a comprehensive report on Oral Mucositis pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.

Current status, developmental phase, participating companies and entities, recent developments, orphan drug/fast track/other designations, drug class are provided for each Oral Mucositis pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.

In addition to complete details of each product, the report provides key trends in Oral Mucositis pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.

Contents

1 TABLE OF CONTENTS

1.1 List of Figures
1.2 List of Tables

2 ORAL MUCOSITIS PIPELINE ANALYSIS

2.1 Disease and Pipeline Overview
2.2 Oral Mucositis Pipeline Snapshot
2.3 Oral Mucositis Pipeline by Phase
2.4 Oral Mucositis Pipeline by Company
2.5 Oral Mucositis Pipeline by Mechanism of Action

3 ORAL MUCOSITIS- COMPANY WISE PIPELINE ANALYSIS

ActoGeniX
BIOCND
Clevexel Pharma
Colby Pharmaceutical Company
Daewoong Pharmaceutical
Enzychem Lifesciences Corporation
Galera Therapeutics
Genekey Biotech Chengdu Co Ltd
GlycoMira Therapeutics
Humanetics Corporation
Hyloris Pharmaceuticals
INC Research Australia Pty Ltd
Innovation Pharmaceuticals
Intrexon
Izun Pharmaceuticals Corporation
Monopar Therapeutics
Mundipharma International Ltd
Novartis Pharmaceuticals
Onxeo S.A.
Oragenics
PolyMedix
Santalis Pharmaceuticals
SciClone Pharmaceuticals, Inc.
Servier Canada Inc
Soligenix In
Spectrum Pharmaceuticals
Spherium Biomed S.L.
SRI International
Sunny Pharmtech
Wellstat Therapeutics Corporation

4 ORAL MUCOSITIS R&D PIPELINE SNAPSHOTS

Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details

5 RECENT DEVELOPMENTS IN ORAL MUCOSITIS PIPELINE

6 APPENDIX

6.1 About VPA Research
6.2 Sources and Research Methodology

List Of Figures

LIST OF FIGURES

Figure 1: Oral Mucositis Pipeline by Phase, H1- 2018
Figure 2: Oral Mucositis Pipeline by Companies, H1- 2018
Figure 3: Company Wise Pipeline Drug Phases, H1- 2018
Figure 4: Oral Mucositis Pipeline by Mechanism of Action, H1- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H1- 2018

List Of Tables

LIST OF TABLES

Table 1: Oral Mucositis Pipeline by Phase, H1- 2018
Table 2: Oral Mucositis Pipeline by Companies, H1- 2018
Table 3: Oral Mucositis Pipeline by Mechanism of Action, H1- 2018
Table 4: ActoGeniX Oral Mucositis Pipeline, May 2018
Table 5: BIOCND Oral Mucositis Pipeline, May 2018
Table 6: Clevexel Pharma Oral Mucositis Pipeline, May 2018
Table 7: Colby Pharmaceutical Company Oral Mucositis Pipeline, May 2018
Table 8: Daewoong Pharmaceutical Oral Mucositis Pipeline, May 2018
Table 9: Enzychem Lifesciences Corporation Oral Mucositis Pipeline, May 2018
Table 10: Galera Therapeutics Oral Mucositis Pipeline, May 2018
Table 11: Genekey Biotech Chengdu Co Ltd Oral Mucositis Pipeline, May 2018
Table 12: GlycoMira Therapeutics Oral Mucositis Pipeline, May 2018
Table 13: Humanetics Corporation Oral Mucositis Pipeline, May 2018
Table 14: Hyloris Pharmaceuticals Oral Mucositis Pipeline, May 2018
Table 15: INC Research Australia Pty Ltd Oral Mucositis Pipeline, May 2018
Table 16: Innovation Pharmaceuticals Oral Mucositis Pipeline, May 2018
Table 17: Intrexon Oral Mucositis Pipeline, May 2018
Table 18: Izun Pharmaceuticals Corporation Oral Mucositis Pipeline, May 2018
Table 19: Monopar Therapeutics Oral Mucositis Pipeline, May 2018
Table 20: Mundipharma International Ltd Oral Mucositis Pipeline, May 2018
Table 21: Novartis Pharmaceuticals Oral Mucositis Pipeline, May 2018
Table 22: Onxeo S.A. Oral Mucositis Pipeline, May 2018
Table 23: Oragenics Oral Mucositis Pipeline, May 2018
Table 24: PolyMedix Oral Mucositis Pipeline, May 2018
Table 25: Santalis Pharmaceuticals Oral Mucositis Pipeline, May 2018
Table 26: SciClone Pharmaceuticals, Inc. Oral Mucositis Pipeline, May 2018
Table 27: Servier Canada Inc Oral Mucositis Pipeline, May 2018
Table 28: Soligenix In Oral Mucositis Pipeline, May 2018
Table 29: Spectrum Pharmaceuticals Oral Mucositis Pipeline, May 2018
Table 30: Spherium Biomed S.L. Oral Mucositis Pipeline, May 2018
Table 31: SRI International Oral Mucositis Pipeline, May 2018
Table 32: Sunny Pharmtech Oral Mucositis Pipeline, May 2018
Table 33: Wellstat Therapeutics Corporation Oral Mucositis Pipeline, May 2018